You just read:

Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 20, 2016, 07:00 ET